On October 12, 2020 Exact Sciences Corp. (NASDAQ: EXAS) reported the introduction of the Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer (Press release, Exact Sciences, OCT 12, 2020, View Source [SID1234568328]). The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient’s tumor profile and effectively recommend targeted therapies or clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Exact Sciences Introduces the Oncotype MAP Test to Help Guide Treatment for Patients with Advanced Cancer
"Exact Sciences is pursing life-changing answers that give people the clarity to take action earlier. Our growing Precision Oncology portfolio and the addition of the Oncotype MAP test allow us to do just that for patients fighting late-stage or metastatic cancer," said Kevin Conroy, chairman and CEO of Exact Sciences. "Patients with advanced cancer need answers fast, and providing them with actionable results in days, rather than weeks, is critical for improving their outcomes."
Key attributes and differentiators of the Oncotype MAP test include:
fast turnaround time of 3-5 business days1,2 to guide timely treatment decisions,
small sample requirements with as little as 3 mm2 of tissue or 2-3 slides3,
highly accurate1 and comprehensive results using next generation sequencing and immunohistochemistry, and,
based on a study from a previous generation of the test, a significantly increased rate of progression-free survival when compared to patients who did not utilize the test (43% vs. 5%)4.
The Oncotype MAP test report is easy to interpret with NCCN Compendium-based recommendations, along with potential evidence-based therapies and clinical trials. The report is currently tailored to support clinical decision making by showing actionable biomarkers associated with more than 100 evidence-based therapies, over 45 combination therapies, and more than 650 active clinical trial associations. By delivering insights into targeted therapy options, the Oncotype MAP test is designed to address the needs of more than 500,000 patients who face advanced cancer each year in the United States5.
"The systemic treatment of patients with advanced or metastatic cancer is challenging," said Rick Baehner, MD, chief medical officer of Precision Oncology at Exact Sciences. "Oncotype MAP is a tissue-based assay which delivers results regarding the underlying biology of a patient’s cancer and provides therapeutic and clinical trial options. Genomic results guide clinicians to individualize and optimize oncology therapy by targeting patient tumor biology with the most effective therapies."
The Oncotype MAP test is currently available for physicians in the U.S. to order at www.OncotypeMAP.com. Medicare covers the Oncotype MAP test for qualifying members and commercial coverage varies by insurance plan and patient benefit level.